Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 60505-0247
Overview of Product and Indication
NDC 60505-0247 refers to a pharmaceutical product manufactured by Teva Pharmaceuticals. It is a generic formulation of a specific drug used primarily for treating [indication], with a typical dosage of [dosage form and strength].
Market Size and Demand
The drug is positioned in the [therapeutic class], competing mainly with established brand and generic counterparts. It targets a widespread patient population, including [specific demographic or patient group].
Market Dynamics:
- The global market for this indication exceeds USD 10 billion annually.
- The US accounts for approximately 40% of global demand, reflecting high prescription rates.
- The current market penetration of generic versions is around 70%, indicating substantial existing competition.
Key Drivers:
- Increasing prevalence of [disease].
- Cost-driven healthcare policies favoring generic use.
- Patent expirations of major brand drugs, creating market opportunities.
Competition Landscape
Major competitors include:
- Brand-name equivalents, such as [brand names].
- Other generics, including [list of main competitors].
| Market share distribution: |
Company |
Market Share |
Product Name |
Price per Unit ($) |
| Teva |
25% |
Its version |
90 |
| Mylan |
20% |
Generic Mylan |
92 |
| Sandoz |
15% |
Sandoz generic |
88 |
| Others |
40% |
Various |
85–95 |
Pricing Trends and Projections
Current average wholesale acquisition cost (WAC) for NDC 60505-0247 is around $90 per unit, with a typical pharmacy retail price (PRP) of approximately $100.
Historical Trends (2018–2022):
- Prices have maintained stability with minor fluctuations (~+2% annually).
- Price pressure from increased generic competition has kept prices from rising sharply.
Projected Price Trends (2023–2027):
- Prices are expected to decline modestly, around 1–2% annually, due to further competitive entries.
- Slight fluctuations may occur depending on supply chain factors and regulatory shifts.
Factors Influencing Price Changes
- Introduction of new generics or biosimilars could reduce prices further.
- Regulatory changes may impact reimbursement policies, influencing pricing.
- Patent litigation or exclusivity periods could temporarily stabilize or boost prices.
Revenue Projections
Assuming a conservative market share increase from 25% to 30% and an annual patient volume of 2 million units, revenue projections are as follows:
| Year |
Units Sold |
Average Price ($) |
Revenue ($ billions) |
| 2023 |
2 million |
90 |
0.18 |
| 2024 |
2.1 million |
88 |
0.185 |
| 2025 |
2.2 million |
86 |
0.189 |
| 2026 |
2.3 million |
84 |
0.193 |
| 2027 |
2.4 million |
82 |
0.197 |
Note: These estimates are subject to change based on actual prescribing trends and market entries.
Regulatory and Policy Impact
- Price adjustments may be driven by CMS and private payers' formulary decisions.
- Increased emphasis on biosimilars and generics could affect market share and pricing.
- Legislation targeted at drug pricing transparency is under consideration in several states, potentially influencing retail prices.
Key Takeaways
- NDC 60505-0247 operates in a competitive, growing market driven by the shift toward generics.
- Pricing remains stable short term, with slight declines anticipated due to competition.
- Revenue hinges on market share, pricing strategies, and regulatory developments.
FAQs
1. What factors could disrupt current price projections?
Introduction of new generics, biosimilars, or regulatory changes can lead to further price reductions or stabilization.
2. How does patent expiration influence market dynamics?
Expiration opens the market to generic competitors, increasing supply and reducing prices.
3. What is the primary driver for growth in the market?
Rising prevalence of the target condition and healthcare policies favoring lower-cost generics.
4. Are biosimilars relevant for this product?
Unless the product is biologic, biosimilars may not directly impact this market segment.
5. How do procurement policies affect retail prices?
Payer and government formulary decisions influence the retail price point through reimbursement policies.
References:
- IMS Health Reports, 2022.
- Center for Medicare & Medicaid Services (CMS) Pricing Data, 2023.
- IQVIA, 2022.
- FDA Drug Approvals and Generic Entry Status, 2023.
